Overview

A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

Status:
RECRUITING

Trial end date:
2025-04-30

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of JP-1366 tablets and Nexium (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.

Phase:

PHASE3

Details

Lead Sponsor:

Livzon Pharmaceutical Group Inc.

Treatments:

Esomeprazole